Gastroenterology -Therapeutics & Hepatology

Gastrointestinal Stromal Tumors: Novel Therapies

Gastrointestinal stromal tumors (GISTs) are rare malignancies originating from interstitial cells of Cajal in the digestive tract. Recent advancements in novel therapies are significantly improving treatment outcomes for patients with GISTs. The introduction of targeted therapies, particularly tyrosine kinase inhibitors (TKIs) such as imatinib, sunitinib, and regorafenib, has revolutionized GIST management. These drugs specifically inhibit the abnormal proteins driving tumor growth, offering substantial efficacy and improved survival rates. Emerging treatments are exploring second-generation TKIs and combination therapies to address resistance and progression in cases where initial therapies become less effective. Additionally, research into novel agents, including immune checkpoint inhibitors and therapies targeting specific molecular pathways involved in GISTs, is underway. Advances in personalized medicine, such as genomic profiling, are facilitating tailored treatment approaches that optimize efficacy and minimize side effects. These novel therapies are enhancing the management of GISTs, providing hope for better outcomes and personalized care.